Mauro, Michael J. http://orcid.org/0000-0002-2251-4032
Hughes, Timothy P.
Kim, Dong-Wook
Rea, Delphine
Cortes, Jorge E. http://orcid.org/0000-0002-8636-1071
Hochhaus, Andreas http://orcid.org/0000-0003-0626-0834
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Breccia, Massimo http://orcid.org/0000-0003-1163-6162
Talpaz, Moshe
Ottmann, Oliver
Minami, Hironobu
Goh, Yeow Tee http://orcid.org/0000-0002-7069-0997
DeAngelo, Daniel J. http://orcid.org/0000-0001-7865-2306
Heinrich, Michael C. http://orcid.org/0000-0003-3790-0478
Gómez-García de Soria, Valle
le Coutre, Philipp
Mahon, Francois-Xavier
Janssen, Jeroen J. W. M.
Deininger, Michael
Shanmuganathan, Naranie http://orcid.org/0000-0001-5895-8797
Geyer, Mark B. http://orcid.org/0000-0001-5248-9117
Cacciatore, Silvia
Polydoros, Fotis
Agrawal, Nithya http://orcid.org/0000-0003-4279-8324
Hoch, Matthias
Lang, Fabian
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 2 December 2022
Revised: 27 January 2023
Accepted: 21 February 2023
First Online: 22 March 2023
Competing interests
: MJM: Bristol Myers Squibb, Takeda, and Pfizer: personal fees. TPH: Novartis, Bristol Myers Squibb, and Enliven: consultancy, research funding. D-WK: Novartis, Bristol Myers Squibb, Pfizer, IL-YANG, and Takeda: grants. DR: Novartis, Pfizer, and Incyte: personal fees. JEC: Novartis, Pfizer, and Bristol Myers Squibb: grants, consulting fees. AH: Bristol Myers Squibb, Pfizer: institutional research support; Novartis and Incyte: institutional research support, personal fees. KS: Novartis: research funding, honoraria. MB: Bristol Myers Squibb, Celgene, Pfizer, Incyte, and Novartis: consultancy and honoraria; AbbVie: consultancy. MT: IMAGO: consultancy; Novartis and Takeda: research funding; Constellation Pharmaceuticals and Bristol Myers Squibb: membership on board of directors or advisory committees. OO: Amgen, Incyte, Celgene, Roche, Fusion Pharma, Novartis: honoraria. Amgen, Incyte, and Celgene: research funding. HM: Bayer, Bristol Myers Squibb Japan, Celgene, Chugai Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Kyowa Hakko Kirin, Lilly Japan, Novartis, Ono Pharmaceutical, Otsuka, Pfizer, Taiho Pharmaceutical, Takeda, MSD, and AbbVie: honoraria; Ono Pharmaceutical: consulting; Astellas Pharma, Chugai Pharma, Dainippon Sumitomo Pharma, Eisai, Kyowa Hakko Kirin, Lilly Japan, Ono Pharmaceutical, Taiho Pharmaceutical, Nippon Shinyaku, MSD, Boehringer Ingelheim, Daiichi Sankyo, Takeda, Nihonkayaku, Shionogi, Sanofi, Bayer Schering Pharma, Mitsubishi Tanabe Pharma, and Teijin Pharma: research funding. YTG: Pfizer, Johnson & Johnson, Amgen, MSD Pharma, Novartis, EUSA Pharma, Roche, Bristol Myers Squibb, and AbbVie: honoraria. DJD: AbbVie, Novartis, Blueprint, and GlycoMimetics: grants; AbbVie, Novartis, Blueprint and GlycoMimetics: research funding; AbbVie, Amgen, Autolus, Blueprint, Forty-Seven, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda; consulting. AbbvVie, Amgen, Autolus, Blueprint, Forty-Seven, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda: personal fees. MCH: Novartis, Deciphera, Theseus and Blueprint Medicines: consultancy; Deciphera: speaker’s bureau; Jonathan David Foundation, VA Merit Review Grant (I01BX005358), and NCI R21 grant (R21CA263400): partial salary support. Prior to 2019, MCH held an equity interest in MolecularMD. MCH holds multiple patents on the diagnosis and/or treatment of gastrointestinal stromal tumors; one patent on treatment has been licensed by Oregon Health & Science University to Novartis. VGGdS: Novartis, Pfizer, Bristol Myers Squibb, and Incyte: grants, nonfinancial support, and honoraria. PC: Pfizer, Novartis, and Incyte: honoraria. F-XM: Novartis: grants, honoraria, consultancy, and research funding; Bristol Myers Squibb and Pfizer: honoraria. JJWMJ: Novartis and Bristol Myers Squibb: research funding; Incyte: speaker’s fee; AbbVie, Novartis, Pfizer, and Incyte: honoraria; AbbVie, Alexion, Amgen, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Janssen-Cilag, Olympus, Incyte, Sanofi Genzyme, Servier, Jazz, and Takeda: support for Apps for Care and Science nonprofit foundation of which JJWMJ is president. MD: Fusion Pharma, Blueprint, Pfizer, Novartis, Medscape, and Sangoma: consultancy; Pfizer: research funding; Takeda, Sangomo, and Blueprint: membership on board of directors or advisory committees. NS: Novartis: honoraria. Amgen: support for attending meetings and/or travel. MBG: National Cancer Institute, Amgen, Sanofi, Actinium Pharmaceuticals, Inc.: grants; Allogene: consulting. Sanofi and American Society of Hematology: honoraria. SC, FP, NA, and MH are employees of Novartis. FL: Bristol Myers Squibb, Incyte, and Celgene: consultancy, honoraria; Novartis: consultancy, honoraria, and research funding.
: The protocol was approved by the sites’ institutional review boards or ethics committees and conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization. All patients provided written informed consent.